Objective-Among African Americans, the apolipoprotein L1 (APOL1) risk variants have been associated with various types of kidney disease and chronic kidney disease progression. We aimed to determine whether these same risk variants also confer an increased risk for cardiovascular disease. Approach and Results-In a cohort of African Americans with hypertension-attributed chronic kidney disease followed for up to 12 years, we used Cox proportional hazards models to estimate the relative hazard of a composite cardiovascular disease outcome (cardiovascular death or hospitalization for myocardial infarction, cardiac revascularization procedure, heart failure, or stroke) for the APOL1 high-(2 risk variants) versus low-risk (0-1 risk variant) genotypes. We adjusted for age, sex, ancestry, smoking, heart disease history, body mass index, cholesterol, randomized treatment groups, and baseline and longitudinal estimated glomerular filtration rate, systolic blood pressure, and proteinuria. Among 693 participants with APOL1 genotyping available (23% high risk), the high-risk group had lower mean estimated glomerular filtration rate (44.7 versus 50.1 mL/min per 1.73 m 2 ) and greater proteinuria (median 0.19 versus 0.06) compared with the low-risk group at baseline. There was no significant association between APOL1 genotypes and the composite cardiovascular disease outcome in both unadjusted (hazard ratio=1.23; 95% confidence interval: 0.83-1.81) and fully adjusted (hazard ratio=1.16; 95% confidence interval: 0.77-1.76) models; however, in using an additive model, APOL1 high-risk variants were associated with increased cardiovascular mortality. Conclusions-Among African Americans with hypertension-attributed chronic kidney disease, APOL1 risk variants were not associated with an overall risk for cardiovascular disease although some signals for cardiovascular mortality were noted. Visual Overview-An online visual overview is available for this article.
C ardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD), with the risk for CVD mortality increasing incrementally as kidney function declines. [1] [2] [3] Compared with European Americans, African Americans are at heightened risk for all-cause mortality and CVD associated with CKD. 4 Although racial disparities in traditional risk factors and quality of care exist, genetic susceptibilities may also contribute.
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Among African Americans, risk variants in the gene encoding apolipoprotein L1 (APOL1) have been associated with many types of kidney disease. [6] [7] [8] [9] [10] Parsa et al 10 reported
in the AASK (African American Study of Kidney Disease and Hypertension) that individuals with 2 copies of the APOL1 high-risk variants had a ≈2-fold greater risk of CKD progression compared with individuals with 0 or 1 copy. Whether these risk variants also confer an increased risk for CVD is uncertain because results from the few available studies have been conflicting. [11] [12] [13] [14] [15] In the JHS (Jackson Heart Study), the WHI (Women's Health Initiative), and the CHS (Cardiovascular Heart Study), the APOL1 high-risk variants have been associated with an increased risk of adverse cardiovascular events. 11, 16 Other studies, however, have suggested no association between the risk variants and CVD.
not have established CKD. Thus, how APOL1 relates to CVD in the context of reduced kidney function remains unknown.
With up to 12 years of follow-up from the well-characterized population of AASK, we aimed to determine whether the APOL1 high-risk variants were associated with an increased risk for CVD outcomes in African Americans with hypertension-attributed CKD.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Baseline Characteristics
Among the 693 AASK participants with APOL1 genotyping available, 33 (21%) individuals with the APOL1 high-risk genotypes (2 risk variants) and 111 (21%) individuals with the low-risk genotypes (0-1 risk variant) experienced the composite CVD outcome, which consisted of cardiovascular death or hospitalization for nonfatal myocardial infarction, cardiac revascularization procedure, heart failure, or stroke before the onset of end-stage renal disease (ESRD). At baseline, individuals with the APOL1 high-risk genotypes were younger (mean age: 51.7 versus 54.8 years) and had lower estimated glomerular filtration rates (mean: 44.7 versus 50.1 mL/min per 1.73 m 2 ) and greater proteinuria (median urine protein-tocreatinine ratio: 0.19 versus 0.06 g/g Cr) compared with those with the low-risk genotypes. History of heart disease was less common in the APOL1 high-risk group compared with the low-risk group (43% versus 53%, respectively; Table 1 Table 2 ). Similar results were obtained when analyses were repeated using an additive or dominant genetic model (data not shown).
In sensitivity analyses, we found no significant association between APOL1 risk status and individual components of the composite CVD outcome in fully adjusted recessive genetic models ( Values presented as mean±SD, median (interquartile range), or n (%). APOL1 high risk defined as having 2 risk variants and low risk defined as having 0 to 1 risk variant. APOL1 indicates apolipoprotein L1; Cr, creatinine; and eGFR, estimated glomerular filtration rate.
Discussion
Among African Americans with CKD attributed to hypertension, the APOL1 high-risk genotypes were not associated with an increased risk for CVD events. These results were consistent in crude analysis, analysis adjusted for demographics, traditional risk factors, and kidney function, further adjustment for longitudinal systolic blood pressure, estimated glomerular filtration rate, and log-transformed proteinuria, and when we accounted for the competing risks of ESRD and death. Furthermore, the APOL1 high-risk genotypes were not associated with any single component of the CVD composite outcome with the exception of cardiovascular death (additive model only). These findings add to the growing body of literature on the APOL1 risk variants and CVD in the general population. 11, 12, 15, 16 Consistent with our study, the SPRINT (Systolic Blood Pressure Intervention Trial) and Atherosclerosis Risk in Communities study suggested no association between the APOL1 high-risk variants and prevalent 12 or incident CVD, 15 respectively. However, in the JHS and the WHI, individuals with 2 APOL1 risk variants compared with those with no risk variant had a 1.8-to 3.2-fold higher risk of experiencing a major adverse cardiovascular event. 11 In the CHS, a cohort of adults aged ≥65 years, the APOL1 high-risk genotypes were associated with an increased risk for incident myocardial infarction but not stroke or congestive heart failure. 16 Our study population is unique in that it consisted of individuals with moderate CKD (mean estimated glomerular filtration rate, 45 mL/min per 1.73 m 2 for APOL1 high-risk and 50 mL/min per 1.73 m 2 for low-risk groups), whereas the other studies included individuals with mild or no CKD (mean estimated glomerular filtration rates from 73 to 112 mL/min per 1.73 m 2 ). 11, 12, 15, 16 Like SPRINT, 12 another negative study on the association of APOL1 with CVD, AASK excluded individuals with diabetes mellitus. Perhaps, the association between APOL1 risk variants and CVD differs in the context of diabetes mellitus. In the 3 cohorts that reported a positive association between the APOL1 high-risk variants and CVD, approximately one quarter of participants had a history of diabetes mellitus. 11, 16 Our study has frequent assessments of kidney function, allowing for the investigation of mediation by change in kidney function; in contrast, the analyses in SPRINT were limited to prevalent, self-reported CVD. 12 In support of our findings, associations between APOL1 risk variants with subclinical CVD have been largely negative. Although apolipoprotein L1's role in trafficking of highdensity lipoprotein 17 and expression within endothelial and smooth muscle cells could suggest a role in CVD, 18, 19 Ito et al 11 reported an association between the APOL1 risk variants and lower Agatston scores (as a measure of coronary artery calcium) in the JHS. Similarly, the APOL1 risk variants were associated with less carotid and coronary artery calcified plaques in the AA-DHS (African American Diabetes Heart Study). 13 Freedman et al 14 reported that the APOL1 risk variants were associated with less white matter lesion volume (a marker of severe cerebral small vessel disease) in the AA-DHS MIND (Memory IN Diabetes).
We did find an association between the number of APOL1 risk variants and an increased risk for cardiovascular death; however, this was only when using the additive genetic model. These results should be interpreted with caution because they may be spurious in the context of multiple testing and few events (n=31) for this secondary outcome. To our knowledge, only one other study has examined the association between APOL1 risk variants and cardiovascular mortality. In the CHS, risk for cardiovascular Figure. Kaplan-Meier survival curves for composite cardiovascular events by apolipoprotein L1 (APOL1) risk status.
mortality was not significantly greater among individuals with 2 APOL1 risk variants compared with individuals with 1 or no variants although a modest increase for total and noncardiovascular mortality was noted. 16 Other studies have reported either improved survival 13, 20 or no difference in risk for all-cause mortality 15 associated with the APOL1 high-risk variants. Our study has several strengths. First, we used a wellcharacterized cohort of African Americans in which data were collected prospectively with an active follow-up process. Second, all CVD events were centrally adjudicated by trained clinicians using a common protocol. [21] [22] [23] Third, given the known associations between the APOL1 risk variants and kidney disease, the results of our study are applicable to a large proportion of patients seen in clinical practice who are already at increased risk for CVD because of their underlying CKD. Finally, our findings were robust, with similar conclusions obtained when using additive or dominant genetic models and after accounting for competing risks (ESRD and death).
Limitations include a relatively small number of outcome events, which may have limited our power to detect associations between the APOL1 risk variants and CVD. With only 144 cases of the composite CVD outcome, we had 80% power to detect a minimum HR of 1.85 for the APOL1 high-risk compared with the low-risk genotypes (recessive genetic model). Still, this HR is within the range of what was reported in the JHS and WHI. 11 Our sensitivity analyses examining secondary end points were likely underpowered, particularly for cardiovascular death, which had the fewest number of events (minimum detectable HR of 3.74 for 80% power). Furthermore, study participants were not followed for CVD events once they developed ESRD. There may have been additional cases of CVD that were not captured; however, the pathophysiology of CVD events post-ESRD (ie, more sudden cardiac death) likely differs from that of pre-ESRD CVD events. 24 In conclusion, we did not detect an association of APOL1 high-risk variants with a composite CVD outcome in African Americans with CKD attributed to hypertension. Sensitivity analyses, however, suggested an increased risk of cardiovascular death associated with increasing number of APOL1 risk variants. Our results are consistent with some, but not all, prior studies. In view of the common association of CVD with kidney disease, additional research is warranted to better understand whether the APOL1 risk variants are associated with CVD outcomes, and if so, the pathophysiological basis for an association. 
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